This was a phase II efficacy study assessing the combination of olaparib and paclitaxel in gastric cancer patients, which identified a greater overall survival benefit in patients with “ATM-low” tumours.40 Here “ATM-low” tumours were defined as those with ≤10% ATM tumour cell nuclear staining, quantified by an IHC test using the ATM (Y170) antibody clone. This evidence concerns the gene ATM and gastric cancer.